Program
fanregratinib
Also written as “HMPL-453”, “HMPL-453 with Itraconazole” and “HMPL-453 with Rifampin”.
Its studies are mostly in Cholangiocarcinoma · Stomach Neoplasms · Mesothelioma, Malignant, led by HUTCHMED.
Furthest: phase 3, since Apr 16, 20208 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HUTCHMED | 81 open or running | phase 3since Apr 16, 2020 | Oct 27, 2016 | Jun 30, 2028phase 3 · NCT04353375 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2016First study: phase 1 study in Solid TumorFirst studyNCT02966171 · 14 enrolled · Australia
- May 17, 2017Phase 2 study in Solid Tumor, AdultNCT03160833 · 33 enrolled · China
- Jan 17, 2020Phase 2 study in Advanced Malignant MesotheliomaNCT04290325 · 27 enrolled · China
- Apr 16, 2020Phase 3 study in Advanced Intrahepatic CholangiocarcinomaNCT04353375 · 235 planned · China
- Oct 31, 2021Phase 2 study in Stomach NeoplasmsNCT05173142 · 190 enrolled · China
- May 22, 2023Phase 1 study in CholangiocarcinomaNCT05930119 · 24 enrolled · China
- Feb 17, 2025Phase 1 study in Mass Balance StudyNCT07644442 · 6 enrolled · China
- Mar 5, 2025Phase 1 study in Health, SubjectiveNCT07697157 · 40 enrolled · China
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Advanced Intrahepatic CholangiocarcinomaNCT04353375
TargetBeta
FGFR1 →read by rule
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
Other programs on FGFR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07697157Health, Subjective · China | 1 | Completed | Dec 31, 2025 | 40 |
| NCT07644442Mass Balance Study · China | 1 | Completed | Mar 14, 2025 | 6 |
| NCT05930119Cholangiocarcinoma · China | 1 | Completed | Aug 28, 2023 | 24 |
| NCT05173142Stomach Neoplasms · China | 2 | Completed | Jul 17, 2025 | 190 |
| NCT04353375Advanced Intrahepatic Cholangiocarcinoma · China | 3 | Recruiting | Jun 30, 2028 | 235 |
| NCT04290325Advanced Malignant Mesothelioma · China | 2 | UNKNOWN | Nov 30, 2022 | 27 |
| NCT03160833Solid Tumor, Adult · China | 2 | UNKNOWN | Dec 31, 2019 | 33 |
| NCT02966171Solid Tumor · Australia | 1 | Terminated | Aug 23, 2018 | 14 |
How it is read
Names in the registry
- “HMPL-453”, 7 entries
- “HMPL-453 with Itraconazole”, 1 entry
- “HMPL-453 with Rifampin”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 2 studies
- Stomach Neoplasms, 1 study
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.